JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Fermé

SecteurSoins de santé

101.13 -1.24

Résumé

Variation du prix de l'action

24h

Actuel

Min

101.02

Max

101.42

Chiffres clés

By Trading Economics

Revenu

123M

795M

Ventes

398M

5.1B

P/E

Moyenne du Secteur

59.135

37.461

Marge bénéficiaire

15.708

Employés

53,000

EBITDA

155M

1.4B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+25.06% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.6B

149B

Ouverture précédente

102.37

Clôture précédente

101.13

Sentiment de l'Actualité

By Acuity

30%

70%

68 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Boston Scientific Corp. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 oct. 2025, 11:00 UTC

Résultats

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17 oct. 2025, 11:43 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23 juil. 2025, 11:16 UTC

Résultats

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22 oct. 2025, 10:32 UTC

Résultats

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 oct. 2025, 10:32 UTC

Résultats

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 oct. 2025, 10:31 UTC

Résultats

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 oct. 2025, 10:31 UTC

Résultats

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q Adj EPS 75c >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q Sales $5.07B >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q EPS 51c >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17 oct. 2025, 11:02 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17 oct. 2025, 11:02 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17 oct. 2025, 11:01 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17 oct. 2025, 11:00 UTC

Acquisitions, Fusions, Rachats

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9 sept. 2025, 12:58 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 sept. 2025, 12:31 UTC

Acquisitions, Fusions, Rachats

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 juil. 2025, 10:32 UTC

Résultats

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 juil. 2025, 10:31 UTC

Résultats

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific 2Q EPS 53c >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific 2Q Sales $5.06B >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific 2Q Adj EPS 75c >BSX

23 juil. 2025, 10:30 UTC

Résultats

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Comparaison

Variation de prix

Boston Scientific Corp. prévision

Objectif de Prix

By TipRanks

25.06% hausse

Prévisions sur 12 Mois

Moyen 126.45 USD  25.06%

Haut 140 USD

Bas 113 USD

Basé sur 24 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

24 ratings

23

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

102.95 / 104.93Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

68 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat